about
Targeting the hepatocyte growth factor-cMET axis in cancer therapyEffect of KRAS oncogene substitutions on protein behavior: implications for signaling and clinical outcomeEpidermal Growth Factor Receptor P753S Mutation in Cutaneous Squamous Cell Carcinoma Responsive to Cetuximab-Based Therapy.Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung CancerThe novel and effective nonplatinum, nontaxane combination of gemcitabine and vinorelbine in advanced nonsmall cell lung carcinoma: potential for decreased toxicity and combination with biological therapy.Phase II study of pemetrexed in combination with carboplatin in the first-line treatment of advanced nonsmall cell lung cancer.Phase II trial of the histone deacetylase inhibitor vorinostat (Zolinza, suberoylanilide hydroxamic acid, SAHA) in patients with recurrent and/or metastatic head and neck cancer.Sunitinib in combination with paclitaxel plus carboplatin in patients with advanced solid tumors: phase I study resultsPhase I study of celecoxib with concurrent irinotecan, Cisplatin, and radiation therapy for patients with unresectable locally advanced non-small cell lung cancerPhase 1b study of motesanib, an oral angiogenesis inhibitor, in combination with carboplatin/paclitaxel and/or panitumumab for the treatment of advanced non-small cell lung cancer.EGFR expression and survival in patients given cetuximab and chemoradiation for stage III non-small cell lung cancer: a secondary analysis of RTOG 0324.The BATTLE trial: personalizing therapy for lung cancer.Phase II study of dasatinib in patients with advanced non-small-cell lung cancerOutcomes of patients with advanced cancer and KRAS mutations in phase I clinical trials.Phase II study of cetuximab in combination with chemoradiation in patients with stage IIIA/B non-small-cell lung cancer: RTOG 0324Role of HGF/MET axis in resistance of lung cancer to contemporary management.Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factoAdding Erlotinib to Chemoradiation Improves Overall Survival but Not Progression-Free Survival in Stage III Non-Small Cell Lung CancerFrequency of mesenchymal-epithelial transition factor gene (MET) and the catalytic subunit of phosphoinositide-3-kinase (PIK3CA) copy number elevation and correlation with outcome in patients with early stage breast cancerPooled Analysis of Individual Patient Data on Concurrent Chemoradiotherapy for Stage III Non-Small-Cell Lung Cancer in Elderly Patients Compared With Younger Patients Who Participated in US National Cancer Institute Cooperative Group Studies.Asian ethnicity as a predictor of response in patients with non-small-cell lung cancer treated with gefitinib on an expanded access program.Epidermal growth factor receptor inhibitors in development for the treatment of non-small cell lung cancer.An epithelial-mesenchymal transition gene signature predicts resistance to EGFR and PI3K inhibitors and identifies Axl as a therapeutic target for overcoming EGFR inhibitor resistance.Phase II trial of single-agent foretinib (GSK1363089) in patients with recurrent or metastatic squamous cell carcinoma of the head and neck.Angiogenesis inhibitors for lung cancer: clinical developments and future directions.Sorafenib in lung cancer: clinical developments and future directions.Advanced malignancies treated with a combination of the VEGF inhibitor bevacizumab, anti-EGFR antibody cetuximab, and the mTOR inhibitor temsirolimus.cMET and phospho-cMET protein levels in breast cancers and survival outcomes.Mesothelin expression and survival outcomes in triple receptor negative breast cancer.Clinical and biomarker outcomes of the phase II vandetanib study from the BATTLE trial.Feasibility of image-guided transthoracic core-needle biopsy in the BATTLE lung trial.Phase II trial of induction chemotherapy followed by surgery for squamous cell carcinoma of the oral tongue in young adults.Clinical outcomes and biomarker profiles of elderly pretreated NSCLC patients from the BATTLE trial.Comprehensive biomarker analysis and final efficacy results of sorafenib in the BATTLE trialMotesanib and advanced NSCLC: experiences and expectations.Long-term safety and tolerability of sorafenib in patients with advanced non-small-cell lung cancer: a case-based review.Immunotherapy for non-small cell lung cancer: novel approaches to improve patient outcome.Developmental antiangiogenic agents for the treatment of non-small cell lung cancer (NSCLC).Local consolidative therapy versus maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer without progression after first-line systemic therapy: a multicentre, randomised, controlled, phase 2 study.Differential expression of hormonal and growth factor receptors in salivary duct carcinomas: biologic significance and potential role in therapeutic stratification of patients.
P50
Q24606259-B58DA049-F7FA-48D8-8832-CB9BF2426227Q27851703-352F8661-5AAC-4276-A25B-E5869FD92B75Q27853020-11299C45-2830-449C-BC73-7C5D15C4EF19Q29620913-60A7A1C9-C433-446F-9E54-E5409E4D5B98Q33343275-54764CFC-AA57-4AC9-9934-B17D54C6A0A5Q33369094-8FE309AB-AB73-4DC5-9612-8098D1EB8BE2Q33377144-DDE2ECF6-8C1E-42E8-83DB-532CBCA45B37Q33393174-BF67543E-78EA-479E-A289-D1474F73FDD2Q33401530-6D1792E2-C0C7-4AE4-BAFF-5E08B6D1189BQ34089521-0C362671-2821-481F-8467-919FDAC6F8A2Q34216725-D157F7FD-99E2-4E2E-963D-F11818903098Q34275011-822C99A6-0239-4228-B2A6-B1C7F8C6CB6AQ34281221-18E7F4B3-450C-4739-9902-702B0539FD96Q34619163-426F32E1-61DA-42DC-91ED-B1558BEF76FAQ35023433-7FF00705-1779-4CDB-9663-F646198052D8Q35200337-5EADA8F1-FE70-4FCB-89DA-6830ADD01A9FQ35568485-61FB3313-7BC9-4C44-A3D9-45C670132A9DQ35608002-639E6337-E883-4A2B-80B4-D0337C740E93Q36287691-8101ED8F-6B53-4D10-93E3-E722254ADEBBQ36368864-B1478628-C709-42DF-9856-6D3B05A36913Q36461000-6788C1D9-5B0B-4B76-8BF5-744CDC479972Q36542497-2DF13596-6A62-491B-89B6-524A5171694BQ36597042-44DA4223-E52E-45C9-AA8A-31AD6B99FC03Q36660533-07F35135-0CC4-4C2B-B7DF-72EB7C640ABAQ36780642-3A0F8D3B-CA4C-42A5-9E1C-5F24D5359C65Q37180219-BCED18E4-BFF1-4F19-ACC3-A4015F3BF338Q37268981-075E2ADF-AD2B-457E-82C2-FBB03B28AC9CQ37290053-1F957FCD-87AB-413A-9B79-80DA606D0FBDQ37339008-1317F3DF-6851-482E-A51E-4D077C451952Q37428434-A3A7B616-ABED-4A2B-BA04-E6F39394D59FQ37429963-4D45C6F8-A3FA-44A7-A749-384860B805D8Q37483635-882B7133-8526-45AE-BDC2-75A5D387883CQ37509502-D26FEED5-E4E3-44FA-8593-EC2755EEB22DQ37526488-D45DFD53-1745-4465-9636-2B249B38B19CQ37870920-EAD5FF3B-A446-4F2E-955A-DBCE3EF6F8A3Q37897376-6F618322-1A2D-4DDC-8A0D-F33F8D5CD3ACQ37923728-AA820D17-D047-4191-A6D7-F74B43867FFBQ37944183-946B02AF-BBBE-46E1-B979-B8AECDDB0858Q38409259-C3288558-F6EF-4207-9268-29476F4EAA59Q38428782-BAD5CEA3-A1A8-4A6C-A277-BEE09A455F82
P50
name
George R Blumenschein
@en
George R Blumenschein
@nl
type
label
George R Blumenschein
@en
George R Blumenschein
@nl
prefLabel
George R Blumenschein
@en
George R Blumenschein
@nl